Research pivot for eFFECTOR after mid-stage disappointment

5 April 2024
biotech_research_lab_pipette_big

A trial flop for eFFECTOR Therapeutics (Nasdaq: EFTR) has prompted the Californian firm to drop development of its lead candidate, tomivosertib, in lung cancer.

The company, which focuses on selective translation regulator inhibitors, plans to carry on with a trial testing the candidate in acute myeloid leukemia (AML).

Announcing top-line results from the Phase II KICKSTART trial, the firm said median progression-free survival (PFS) was 13 weeks, compared with 11.7 weeks for the placebo arm.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical